Biotech Values

[DewDiligence]

…I took a stab at valuing…m-Copaxone. I came up with $330M, which considering that much of the calculation is a series of guesses is within spitting distance of your $250M.

The $250M of value I ascribed to half of the NVS-MNTA Copaxone collaboration could well be conservative. This number will surely have to be raised if the ruling on the Markman hearing suggests that the Copaxone patents in question won’t stand up to legal scrutiny.